Another New Study of Differences in Cancer Drug Spending Could Have 340B Implications

On Friday, the nonpartisan Medicare Payment Advisory Commission (MedPAC) made headlines (see story below) when its staff said it could find no link between evidence of 340B hospitals’ higher spending on drugs to treat prostate and lung cancer and incentives created by 340B discounts. The MedPAC report is expected to include an examination of the effects of patient characteristics on drug spending, something that past research on the subject has struggled to tease out.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

*Sign up for news summaries and alerts from 340B Report